Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies |
| |
| Institution: | 1. Department of Hematology and Bone Marrow Transplantation Center, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey;2. Department of Internal Medicine, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey;1. Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL;2. Division of Hematology-Oncology, Mayo Clinic, Rochester, MN;3. Division of Hematology-Oncology, Mayo Clinic, Phoenix, AZ;4. Division of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, FL;5. St. Barnabas Hospital, Bronx, NY;1. Department of Lymphoma, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, 26600, China;2. Department of Hematology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, 26600, China;3. Department of Hematology, the Eighth People''s Hospital of Qingdao, Qingdao, Shandong, 26600, China;1. Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY;2. Department of Hematology, CHU, Univ. Lille, Lille, France;3. Department of Population Health Science and Policy, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY;1. Department of Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA;2. Division of Biostatistics, Department of Pharmacology and Experimental Therapeutics, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA;3. Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA;1. Department of Medicine, Division of Geriatrics, NYU Long Island School of Medicine, Mineola, NY;2. Department of Medicine, Division of Oncology-Hematology, NYU Long Island School of Medicine, NYU Perlmutter Cancer Center, Mineola, NY;3. Department of Medicine, Division of Hematology/Oncology, NYU Grossman School of Medicine, NYU Perlmutter Cancer Center, New York, NY;1. Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, South Korea;2. Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, South Korea;3. Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Jeollanamdo, South Korea;4. Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, South Korea;5. Department of Nuclear Medicine, Chonnam National University Hwasun Hospital, Hwasun, South Korea |
| |
| Abstract: | IntroductionTumor lysis syndrome (TLS) is a commonly observed oncological emergency that requires prompt diagnosis and treatment. Rasburicase is a recombinant urate oxidase endorsed in TLS for the treatment of hyperuricemia. The effect of single-dose 7.5 mg rasburicase at longer follow-ups was not widely investigated.Patients and MethodsEighty-two patients included in the study with clinical TLS and laboratory TLS. The primary endpoint was the normalization of uric acid (<6mg/dL) within 24 hours of rasburicase administration, which was described as treatment success. The secondary endpoint was defined as having sustained response at the first week. The third endpoint was defined as the reaching the baseline renal function before TLS.ResultsWe found that the use of a 7.5 mg dose of rasburicase controlled uric acid in 74 of 82 (90,2%) patients at the 24th hour. In the first week, uric acid remained at normal levels in 69 of 82 (84,1%) patients. At 24 hours, the TLS risk group was the only predictor for failing uric acid normalization; at the end of the first week, no predictive factor was identified for failing uric acid normalization.ConclusionRasburicase at 7.5 mg dose is an important agent for controlling laboratory and clinical TLS at 24 hours and extending its effect to the first week. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
